In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Myriad gets rights to Encore Pharmaceuticals' MPC-7869

Executive Summary

Myriad Genetics (pharmaceutical and diagnostic products) has received exclusive worldwide development, manufacturing, and marketing rights to Encore Pharmaceuticals' (cardiovascular and antineoplastic drugs) MPC-7869 (formerly E-7869) for prostate, colon, and other cancers. Phase IIa clinical trials have just been completed in prostate cancer.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register